Anlotinib plus Sintilimab

DRUG2 trials

Sponsors

Shanghai Changzheng Hospital, Sun Yat-sen University

Conditions

AnlotinibChemo-free TherapyColorectal CancerFirst-line TreatmentImmunotherapyNon Clear Cell Renal CarcinomaSintilimab

Phase 2

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

CompletedNCT04271813

Shanghai Changzheng HospitalAnlotinib, Chemo-free Therapy, Colorectal Cancer +3

Start: 2020-06-01End: 2024-02-29Updated: 2024-04-23

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Active, not recruitingNCT05220267

Sun Yat-sen UniversityNon Clear Cell Renal Carcinoma

Start: 2022-02-28End: 2026-12-30Target: 44Updated: 2026-07-07

Related Papers

Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial.

2025-09-16

Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.

Journal of Clinical Oncology2025-05-28

Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.

Journal of Clinical Oncology2024-06-011 citations

Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma: Preliminary results from an exploratory prospective clinical study.

Journal of Clinical Oncology2023-06-011 citations